This is a pilot study, and a follow-up study is needed to investigate whether PK2 is a novel therapeutic target for obesity or obesity-related metabolic diseases, such as NAFLD and T2DM. The gene discussed is PROK2; the disease is metabolic dysfunction-associated steatotic liver disease.